AMENDMENTS TO THE CLAIMS

Please cancel Claims 1-13 without prejudice and insert therefore new Claims 14-23. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-13 (canceled)

14. (New) A method of treatment or prevention of a disease associated with deposition of Aβ in the brain comprising administering to a patient in need thereof a therapeutically effective amount of a growth hormone secretagogue in combination with a therapeutically effective amount of at least one agent which modifies the production or processing of Aβ in the brain, said agent being selected from:

(a) compounds which inhibit the secretion of Aβ;

(b) compounds which selectively inhibit the secretion of the 1-42 isoform of Aβ;

(c) compounds which inhibit the aggregation of Aβ; and

(d) antibodies which selectively bind to Aβ.

15. (New) The method of Claim 14 wherein the disease is Alzheimer's disease.

16. (New) The method of Claim 15 wherein the patient suffers from mild cognitive impairment.

17. (New) The method of Claim 16 wherein the patient additionally possesses one or more risk factors for developing Alzheimer's disease selected from:

a family history of the disease; a genetic predisposition to the disease; elevated serum cholesterol; adult-onset diabetes mellitus; elevated baseline hippocampal volume; elevated CSF levels of total tau; elevated CSF levels of phospho-tau; and lowered CSF levels of Aβ(1-42).

18. (New) The method of Claim 14 wherein the growth hormone secretagogue is N-[1(R)-[(1,2-dihydro-1-methanesulfonylspiro[3H-indole-3,4'–piperidin]-1'-yl)carbonyl]-2-(phenylmethyloxy)ethyl]-2-amino-2-methylpropanamide, or pharmaceutically acceptable salt thereof.

19. (New) The method of Claim 14 wherein the amyloid modifier is a γ-secretase inhibitor.

20. (New) The method of Claim 19 wherein the γ-secretase inhibitor is a compound of formula XIa:



XI(a)

and the pharmaceutically acceptable salts thereof, wherein m is 0 or 1, X is Cl or CF_3, and Y is OH, OC_{1-6}alkyl, NH_2 or NHC_{1-6}alkyl.

21. (New) The method of Claim 14 wherein the amyloid modifier is a compound which selectively inhibits the secretion of the 1-42 isoform of Aβ.

22. (New) The method of Claim 21 wherein the amyloid modifier is R-flurbiprofen.

23. (New) A pharmaceutical composition comprising in a pharmaceutically acceptable carrier, a growth hormone secretagogue and an amyloid modifier selected from:

(a) compounds which inhibit the secretion of Aβ;

(b) compounds which selectively inhibit the secretion of the 1-42 isoform of Aβ; and

(c) compounds which inhibit the aggregation of Aβ.